Leading Chinese medical devices maker Mindray Medical International Limited (MR) has announced that it will participate at the “MEDICA 2010” international medical technology trade fair, slated to be held in Dusseldorf, Germany from November 17-20, 2010.

MEDICA is one of the largest international trade fairs for the medical sector with more than 135,000 visitors across the globe are expected to attend the event this year.

Mindray plans to showcase more than 50 devices from its three major product segments at MEDICA 2010. The new products to be demonstrated include the V series patient monitoring system and BS-800 chemistry analyzer. The company will also exhibit its upcoming hematology analyzer BC-6800, planned for launch in 2011.

Mindray reckons the MEDICA 2010 as a major platform to demonstrate its expanding portfolio or high-quality products and its sustained R&D commitment to provide clinicians with the latest technology that enhances patient care. The company is on track to meet its planned 7 to 9 new product launches in 2010.

With its operational headquarters in Shenzhen, China, Mindray is a global Chinese medical devices company. It operates through three segments: Patient Monitoring and Life Support Products, In-Vitro Diagnostic Products and Medical Imaging Systems. Besides China, the company operates in North America, Europe and other Asian countries.

Mindray has a strong position in the low and mid segments of the medical devices market in China and is poised to benefit from the solid fundamentals of the Chinese health care sector. Its new product development initiatives, expanding international footprint (and revenues) and solid sales infrastructure remain encouraging.

Although Mindray’s strength is currently in the low and mid-end segments, the companyis looking to carve a niche in the high-end markets. Moreover, Mindray is well positioned to benefit from the health care reforms in China.However, the company is exposed to intense competition-driven pricing pressure.  

 
MINDRAY MEDICAL (MR): Free Stock Analysis Report
 
Zacks Investment Research